The foot ulcer is one of most common and devastating complications of diabetes and is associated with considerable morbidity and mortality. The major causes of these ulcers are ischemia/hypoxia, neuropathy, and infection, and they often coexist. Despite conventional therapy including revascularization procedures when appropriate, three situations lead frequently to amputation: persistent critical limb ischemia, soft tissue infection, and impaired wound healing from osteomyelitis. The delivery of oxygen to the wound site is crucial in healing diabetic foot ulcers. HBOT works by elevating the plasma oxygen level. HBOT promotes healing by stimulating fibroblast activity and collagen formation and increases fibronectin, which aids in neovascularization.